Partner Stuart Fross was quoted in a Board IQ article, “With Zero-Fee Funds, What’s a Board to Do at 15(c) Time?,” covering what Fidelity’s almost 20 no-fee funds mean for boards during their 15(c) contract renewal process.
Fross shares insights on all effects of the changes, including that, because of these changes, the need to have data on market behavior, investments and funds is now not vital during the 15(c) process. He also said that it’s now unnecessary to do the Gartenberg factors because there is no profitability in it. In addition, though, he points out other outcomes that will come of Fidelity’s new structure, saying that the no-fee funds make it a possibility to negotiate a fund’s investment management fee.
Fross shares insights on all effects of the changes, including that, because of these changes, the need to have data on market behavior, investments and funds is now not vital during the 15(c) process. He also said that it’s now unnecessary to do the Gartenberg factors because there is no profitability in it. In addition, though, he points out other outcomes that will come of Fidelity’s new structure, saying that the no-fee funds make it a possibility to negotiate a fund’s investment management fee.
People
Related News
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."
August 5, 2025
In the News
Aaron Maguregui on Health Data Sharing Plan – 'I would expect the FTC to be heavily involved'
Foley & Lardner LLP partner Aaron Maguregui addressed a new health care data sharing initiative announced by the federal government in the Bloomberg Law article, "Digital Data-Sharing Plan Tests Limits of Health Privacy Rules."